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ABSTRACT
Actinic keratoses (AKs) are common skin lesions
heralding an increased risk of developing
squamous cell carcinoma (SCC) and other skin
malignancies, arising principally due to
excessive ultraviolet (UV) exposure. They are
predominantly found in fair-skinned
individuals, and increasingly, are a problem of
the immunosuppressed. AKs may regress
spontaneously, remain stable or transform to
invasive SCC. The risk of SCC increases for those
with more than 5 AKs, and the majority of SCCs
arise from AKs. The main mechanisms of AK
formation are inflammation, oxidative stress,
immunosuppression, impaired apoptosis,
mutagenesis, dysregulation of cell growth and
proliferation, and tissue remodeling. Human
papilloma virus has also been implicated in the
formation of some AKs. Understanding these
mechanisms guides the rationale behind the
current available treatments for AKs. One of the
main principles underpinning the management
of AKs is that of field cancerization. Wide areas of
skin are exposed to increasing amounts of UV
light and other environmental insults as we age.
This is especially true for the head, neck and
forearms. These insults do not target only the
skin where individual lesions develop, but also
large areas where crops of AKs may appear. The
skin between lesions is exposed to the same
insults and is likely to contain as-yet
undetectable preclinical lesions or areas of
dysplastic cells. The whole affected area is
known as the ‘field’. Management is therefore
divided into lesion-directed and field-directed
therapies. Current therapies include lesion-
directed cryotherapy and/or excision, and
topical field-directed creams: 5-fluorouracil,
imiquimod, diclofenac, photodynamic therapy
and ingenol mebutate. Combining lesion- and
field-directed therapies has yielded good results
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and several novel therapies are under
investigation. Treatment is variable and
tailored to the individual making a gold
standard management algorithm difficult to
design. This literature review article aims to
describe the rationale behind the best available
therapies for AKs in light of current
understanding of pathophysiology and
epidemiology. A PubMed and MEDLINE
search of literature was performed between
January 1, 2000 and September 18, 2013.
Where appropriate, articles published prior to
this have been referenced. This is not a
systematic review or meta-analysis, but aims
to highlight the most up to date understanding
of AK disease and its management.
Keywords: Actinic keratosis; Cryosurgery;
Dermatology; Diclofenac; Field cancerization;




Actinic keratoses (AKs) are defined clinically as
erythematous, scaly plaques that occur on sun-
damaged skin [1] and are a result of exposure to
ultraviolet (UV) radiation. They are typically
located on the face, scalp, neck and extremities
[2–4]. Their potential for malignant
transformation is well documented: they are
known to be precursors of squamous cell
carcinoma in situ (Bowen’s disease) and
squamous cell carcinoma (SCC) [5].
Histology
Actinic keratosis is a proliferation of neoplastic
keratinocytes limited to the epidermis,
characterized by architectural disorder [6, 7].
These features include abnormal keratinocytes
of the basal layer that are variable in size and
shape, nuclear atypia and hyperkeratosis of the
epidermis. Atypical nuclei are enlarged,
irregular, and hyperchromatic.
Any single AK lesion may have one of three
outcomes. It will enter spontaneous remission
[8], remain stable, without further progression,
or transform to invasive squamous cell
carcinoma (SCC) which may rarely metastasize
[7].
The risk of metastasis in invasive SCC cannot
be underestimated, despite variable reporting of
rates. For example, in 2012, a study was
published by Brougham et al. [9] who
examined pathology results from 1997 to 2007
in a large New Zealand retrospective cohort. Of
6,164 patients, they found that cutaneous SCC
(cSCC) metastasizes in 1.9–2.6% of cases.
Certain factors such as larger diameter,
location on the ear and retro-auricular area,
poor differentiation and perineural invasion of
the primary lesion are indicators of increased
risk and should be identified. In this study, 87%
of metastases are to regional lymph nodes,
which is reflective of general statistics. The risk
of nodal metastases ranges from 2.0 to 5.8%
[10, 11] in a recent US single-institution 10-year
cohort, and the risk of disease specific death is
2.1% in anyone diagnosed with cSCC [12].
The risk of progression of AKs is reported in
widely variable figures. Some studies estimated
the risk at 0.075–0.096% per lesion per year, or
about 1% over 10 years [13], with some
estimates as high as 10% over 10 years [14].
However, the Veterans Affairs Topical Tretinoin
Chemoprevention Trial found that the risk of
progression of AK to primary SCC (invasive or
in situ) was 0.6% at 1 year and 2.57% at 4 years
[5]. This study found that the majority of AKs
regressed and, at the end of 5 years, 70% were
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no longer present. Other earlier studies have
found that the risk of progression to invasive
disease is approximately 0.025–16% per year for
any single lesion [14]. For a patient affected by
multiple AK lesions, it has been suggested that
the annual risk of developing invasive
cutaneous SCC lies between 0.15% and 80%
[15]. The relative risk of SCC increases for those
with more than five AK [16]. Whilst it is not
possible to predict which AK lesions will go on
to become SCC, histologic evidence shows that
the majority of SCC arises from AK lesions [17].
Genetics
Actinic keratosis results from the adverse effects
of UV radiation on keratinocyte DNA. The
changes that occur reduce skin immunity and
allow the development of AK [18, 19]. Some
important mutations associated with an
increased risk of progression to SCC are p16
(INK4a) (on chromosome 9p21) [20], p14 (ARF),
p15 (INK4b) and p53. These are implicated in
the development of AK and in progression of AK
to SCC [21]. UV-A (320–400 nm) light is the
most abundant and penetrates skin more deeply
than UV-B. Here it causes oxidative damage to
nucleic acids, membrane lipids and cell proteins
through production of reactive oxygen species
(ROS) [22]. These ROSs interrupt normal cellular
transduction pathways and cell–cell signaling,
causing altered proliferation [23]. The signature
mutations of UV-A are thymine (T) ? guanine
(G), due to the formation of 8-hydroxyguanine
adducts. UV-B (290–320 nm) irradiation directly
causes the formation of cyclobutane pyrimidine
dimers and 6-4 photoproducts, which in turn
give rise to the characteristic cytosine (C) ? T
and CC ? TT mutations [24].
Inactivation of p53, a gene coding for a
tumor suppressor protein, by UV-B light is a
crucial step in the path of creating genetically
unstable keratinocytes [12]. Mutations in the
p53 gene have been found in [90% of human
cutaneous SCCs [12]. P53 in its functional form
has been found to protect against skin cancer
induction by UV light in mice [25]. In the
absence of functional repair genes, such as p53,
other DNA mutations go on to promote
carcinogenesis. Absorbed UV light increases
the production of arachidonic acid and its
metabolites, and other proinflammatory
cytokines. Reactive oxygen species induce
lipid peroxidation and cellular destruction
[26, 27].
The main mechanisms in the formation of
AK, therefore, are inflammation, oxidative
stress, immunosuppression, impaired
apoptosis, mutagenesis, dysregulation of cell
growth and proliferation, and tissue remodeling
[6]. This knowledge is the basis of medical
management for AK.
Due to the ability of AK to regress or lead to
SCC it has traditionally been viewed as
premalignant, but there have been
publications suggesting that reclassification as
‘cancerous’ would be appropriate [28, 29].
Cockerell proposed using the ‘keratinocyte
intraepidermal neoplasia’ (KIN) nomenclature,
in keeping with the classification used for
cervical intraepithelial neoplasia [32].
More recently, infection with cutaneous
human papilloma virus (HPV) has been
associated with the formation of AK [30]. The
exact mechanism is incompletely understood,
but it has been found that the E6 protein of
cutaneous HPV can contribute to reduced levels
of Bak protein. This protein has pro-apoptotic
effects and is usually activated as a protective
mechanism in keratinocytes upon exposure to
UV light [31]. Further discussion is beyond the
scope of this article, but it is an important
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developing area for research into preventative
measures.
It is a challenge to distinguish between AK
and early SCC especially, as they share many
cellular and histopathological features. A
commonly used definition is based on the
relative depth of dysplastic cells within the
skin. AKs can be defined anatomically as an
epidermal lesion of the basal layer that may
extend upwards to involve the granular and
cornified layers [32]. Disease begins in the
basal layer of the epidermis, as this is the site
of dividing cells. Bowen’s disease (squamous
cell carcinoma in situ) lies at the more
extensive end of the epidermal involvement
spectrum, but remains cellularly largely
indistinguishable from AK. Invasive SCC is
defined by extension beyond the epidermis,
through the basement membrane and into
the dermis. However, the diagnosis of
Bowen’s disease must be considered as this
is a malignant tumor contained within the
epidermis with potential for significant
lateral spread and of becoming invasive. It
is also a challenge to distinguish between
Bowen’s disease and SCC histologically,
especially when the SCC is well
differentiated and dermal protrusions are
smooth edged.
In more recent advances, using a
technique of gene expression profiling,
Padilla et al. [33] showed convincingly that
AK is a precursor lesion of SCC, and that
they are closely related genetically. This
study lends credence to the general
consensus that AK lies on a spectrum
between normal skin and SCC. It has also
been shown that reduced p53 staining in
immunohistochemical analysis of AK is
associated with a greater probability of
those lesions developing into SCC [34]. This
may help in future to predict which biopsied
lesions are more likely to require early or
surgical intervention.
Epidemiology
AKs are common among fair-skinned
individuals, and are particularly prevalent in
areas with high levels of sun exposure. In
Australia, AKs are found in 40–50% of the
Caucasian population over the age of 40 years
[35], and reported as 40–60% by Frost and
Green [36]. The prevalence in the United
States ranges from 11 to 26% [37], whilst in
Europe 15% of men and 6% of women have
been reported to be affected [37].
Those who sunburn easily and have difficulty
tanning (Fitzpatrick skin type I and II) are most at
risk of the damaging effects of UV irradiation.
Other risk factors include older age, male gender,
cumulative UV exposure, living closer to the
equator and immunosuppression [38].
Prevalence of AKs is very much age related [39],
reflecting the incidence and recurrence rates that
exceed the rate of regression as people age [40].
Individuals with AKs tend to have 6–8
lesions on average [15]. AKs develop most
commonly on the head, balding scalp, face,
dorsal forearms and hands [41]. It has been
found in one UK study that 75% of all reported
lesions occur on the head, neck and forearms
[42]. Immunocompromised patients notably
have a greatly increased risk of AK. Organ
transplant recipients who are on
immunosuppressive medications are up to 250
times more likely to develop AK [43].
Due to the high prevalence of AK and the
risk for malignant change, AK is an important
subject to address for any physician, but
especially those in primary care and
dermatology. It is likely that most physicians
will be in a position to help prevent either the
serious, or disfiguring sequelae of AK at some
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The most important issue in the management
of AKs is to distinguish between isolated lesions
and multiples, or the occurrence of ‘field
cancerization’. There is no current method to
predict which AK within any given cluster will
progress to invasive malignancy. Due to the
tendency of AKs to develop in certain areas of
skin such as the head and neck, the term ‘field’
has been coined to describe the area of skin
affected. Treatment of the whole ‘field’ targets
visible lesions and also skin which is AK-
adjacent, which is therefore at an increased
risk of developing AKs having been exposed to
similar risk factors.
‘Field cancerization’ is a term that was
originally coined by Slaughter et al. in 1953
[44, 45] referring to histologically abnormal
epithelium adjacent to tumor tissue (within the
aerodigestive region) and was designed to
explain the occurrence of multiple primary
tumors as well as locally recurrent cancer. In
AK it is thought that preclinical damage to the
epidermis should be treated to prevent
progression to more advanced disease. Once a
patient is diagnosed with AK, it is necessary to
decide the first steps in management. An
algorithm showing recommended treatment
options is shown in Fig. 1.
A Comparison of International Guidelines
for Management of AKs
In a comparison of international
recommendations [46–49] on the management
of AKs from Australia, the US, the UK and
Europe, it was found that for single lesions
Australian, European and American guidelines
recommend cryotherapy; whereas, the British
guidelines were notably the only set that specify
that no therapy or sunblock alone would be an
appropriate course of action for mild or thin
lesions. The British guidelines recommend that
if there are patient or clinical concerns for single
lesions then salicylic acid followed by
5-fluorouracil (5-FU), imiquimod, diclofenac,
tretinoin or cryotherapy is the treatment of
choice. Australian and European guidelines for
single lesions also include 5-FU and
photodynamic therapy (PDT), respectively.
For hyperkeratotic lesions, Americans and
Europeans recommend dermabrasion alone, but
Australians and British suggest curettage, with
Australians going on to include double-freeze
cryotherapy and surgery.
For multiple lesions, there appears to be wide
consensus between the Americans, British,
Europeans and Australians on the use of the
field therapy 5-FU. Australia, US and Europe
include imiquimod for multiple lesions while
the UK recommends PDT and diclofenac. PDT is
also recommended by the Australians. Resistant
AKs are treated with 5-FU, imiquimod, PDT
or a diclofenac/cryotherapy combination in
Australia, whilst this is dealt with by surgical
excision or curettage in the UK and imiquimod
in the US. For situations where surgery or other
therapies are inappropriate, Australian
guidelines recommend imiquimod or PDT,
Europeans suggest retinoids and the US
recommends persisting with 5-FU.
It is currently not considered appropriate to
make direct comparisons of efficacy between
different therapies for AKs due to the wide
variability of the studies performed. Numbers of
patients and study designs are not currently
standardized, making valid comparisons very
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difficult. With current knowledge, a chart or
table aiming to make this comparison may be
misleading until further studies are performed
using standardized trial structures. The authors
of this paper recommend this as a valuable
direction for future research. It is noted,
however, that a meta-analysis of 8
interventions for AKs by Gupta and Paquet
[50] was published in August 2013. This is a
follow-up on a prior Cochrane review of the
same treatments. The results indicate that 5-FU
is the most efficacious treatment followed by a
combination treatment of 5-aminolevulinic
acid (ALA) PDT; imiquimod; ingenol mebutate
and 5-methylaminolaevulinate (MAL) PDT. The
remaining treatments of cryotherapy,
diclofenac with hyaluronic acid and placebo
gave a lower efficacy ranking, respectively.
As seen in the previous discussion, AK can
present as a single lesion, or multiple lesions
within a field. Treatment can therefore be
divided up into lesion-specific therapy, or
field-directed therapy. Surgical solutions are
aimed at individual AK lesions (or small
Fig. 1 Decision-making steps in the management of
actinic keratosis (AK) [2]. Copied and modiﬁed with
permission from, Stockﬂeth [2], and from original
publication Stockﬂeth et al. [133]. 5-FU 5-ﬂuorouracil,
ALA 5-aminolevulinic acid, PDT photodynamic therapy
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clusters of identifiable AKs), and field therapy is
most usefully delivered topically, or orally in
very advanced cases that include the
development of multiple SCCs. Often, a
combination of lesion-specific and field-
directed therapies is the most effective
approach, when tailored appropriately to the
patient’s clinical picture. The advantage of
topical field-directed therapy is the ability to




Cryotherapy or cryosurgery with liquid
nitrogen for individual lesions is quick, and
easily performed by the physician [51]. This is
the most common ablative therapy for AKs [52].
However, at present there is no widely accepted
standard method of application and further
studies are required to guide recommendations
more effectively.
The treatment is delivered by either spray or
contact, destroying the epidermal keratinocytes
by freezing. Keratinocytes die at approximately
-40 to -50 C, liquid nitrogen is delivered at
-195.8 C. Dermal structures such as collagen,
nerves and blood vessels are preserved due to
their relative tolerance of low temperatures.
Success of treatment is operator dependent.
The correct method is to freeze the epidermis,
creating an ice ball. A blister should then form,
providing evidence that the basement
membrane has separated from the dermis. This
technique, on thinner lesions, has been shown
to yield 90% clearance at 6 months [53].
Thai et al. [52] performed a prospective,
multi-center study of 90 patients, evaluating
the efficacy of cryosurgery for AK. They found
that the overall complete response rate (100%
lesion clearance) was 67.2%. This was relative to
freeze time (from formation of ice ball to
commencement of thawing), and revealed that
there was 39% response for\5 s of freezing. The
rate was up to 83% for freezing periods [20 s.
Most physicians would suggest that a freezing
time between 5 and 10 s is sufficient to optimize
the tradeoff between efficacy and side effects.
The cost is low and therapy is generally well
tolerated by patients. The procedure is
uncomplicated and adequately clears
abnormal tissue for identifiable lesions [54].
Disadvantages include pain and erythema,
and reduced efficacy in hyperkeratotic lesions
[54]. Aggressive therapy may cause
depigmentation and scarring [52, 55].
Hypopigmentation occurs in 29% of cleared
lesions, while hyperpigmentation may occur in
up to 6% of cases [52]. This is due to the
susceptibility of melanocytes to freezing.
Individual lesions are treated, without
consideration for subclinical epidermal
changes in between lesions, and it cannot be
used for large areas. Repeat treatment is
therefore often necessary as recurrence rates
range from 1.2 to 12% within 12 months [47].
Surgical management such as curettage,
shave excision or conventional excision are
normally reserved for hyperkeratotic lesions or
suspected invasive SCC. Surgical field-directed
therapies such as laser resurfacing, chemical
peels and dermabrasion are effective for
eradication of AK. However, they carry a small
risk of infection and widespread scarring, and
are not frequently performed solely for the
management of AK [56, 57].
There is currently no clear guideline
regarding the specific density of AK lesions per
unit skin area that would indicate a move from
lesion-directed to field-directed therapy, and
this is usually a decision made on clinical
judgment. Moving from field-directed topical
therapies to lesion-directed surgical excision
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would be indicated if there was evidence of
invasive SCC.
Field-Directed Therapy
Currently available agents are 5-FU, imiquimod,
diclofenac, PDT and ingenol mebutate.
5-Fluorouracil Cream: Anti-neoplastic Agent
Topical 5-fluorouracil (5-FU) has had a place in
the treatment of AK for many decades [58]. It is
a pyrimidine analog, which disrupts DNA
formation by stopping the conversion of
deoxyuradilic acid to thymidylic acid [59].
This prevents cell proliferation preferentially
in rapidly dividing cells, especially those of AKs
and basal layers of the epithelium. 5-FU is
available as a cream in 5, 1 and 0.5%
concentrations, and as a solution in 5% and
2% concentrations. It is the most established
field treatment for AK, and is considered by
some the traditional gold standard to which all
other topical agents are compared [1]. The
typical treatment regime is either 5% cream
twice daily or 0.5–1% cream daily for 2–4 weeks.
The widespread application has the advantage
of treating clinically undetectable AKs.
5-FU causes inflammation, erosion, and
ulceration during treatment, which is
necessary for therapeutic success. For a
standard 3- to 4-week period of twice daily
application, these side effects arise after the first
week and subside approximately 2 weeks after
application has ceased, when re-
epithelialization has occurred. These transient
side effects can result in non-compliance.
0.5% 5-FU cream was developed in an
attempt to reduce the inflammation associated
with application. It is applied once daily for a
month. In 2010, Kaur et al. [60] analyzed
clinical trials from 1965 to 2009 to compare
the efficacy of 5% and 0.5% 5-FU cream in
treating multiple AKs of the face and scalp. They
found that after 4 weeks of treatment, complete
clearance for 0.5% 5-FU ranged from 16.7% to
57.8%, and for 5% 5-FU clearance ranged from
43% to 100%. The 5% 5-FU cream had a higher
rate of adverse events. It was also stated that
there is lack of high-powered clinical trials
comparing both groups. However, it appears
that 5% 5-FU gives the greater chance of
complete clearance despite side effects and
should therefore be the preferred treatment.
In 2012, Rhavar et al. [61] performed a
systematic review of 103 studies into the
efficacy of 0.5% 5-FU. Only four studies were
found to be suitable randomized vehicle-
controlled trials. Of 668 patients, the
percentage achieving complete clearance of
their AKs in the 5-FU group was 19, 28.2 and
52.6% in the 1-, 2- and 4-week-treatment
groups. Only 0.85% of those in the vehicle-
treated group reached complete clearance. The
mean lesion count reduction was 90.2% and
28.3% in the 5-FU and vehicle groups,
respectively. It was found by Yentzer et al. [62]
that 0.5% 5-FU cream had a high adherence rate
of 86% to the once daily application over a
4-week period. After 4 weeks of twice daily
application of 5% 5-FU, sustained complete
field clearance at 12 months was seen in 33%
of patients [63].
A number of different methods of reducing
side effects have been tried. The application of
topical corticosteroids 15 min after 5-FU cream
can be helpful to reduce the inflammatory
response, and intermittent use of 5-FU cream
can cause reduced side effects.
Intermittent, or pulsed 5-FU application is
not as widely used currently as previously, but
has been shown to reduce side effects, whilst
maintaining efficacy for the treatment of AK
[64, 65]. Labandeira et al. [64] studied the effects
of four applications per week for the first week,
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followed by two applications per week if
irritation was intolerable. One disadvantage to
this regime is that the time to complete healing
of lesions is prolonged with reduced frequency
of application, but remains moderately effective
in treating AKs.
The use of corticosteroid creams and pulsed
therapy may reduce the efficacy of 5-FU
treatment [66]. Side effects can also be
minimized in practice by choosing to treat
smaller areas only, or visible lesions only after
the first week. Exposure to sunlight should be
minimal as the treated area is photosensitive
and exposure can cause pain.
Imiquimod: Immunomodulator Agent
Imiquimod is an imidazoquinolone immune
response modifier that acts on both innate and
acquired immunity. It is a toll-like receptor-7
agonist that modifies the immune response in
the skin and stimulates apoptosis, thereby
disrupting tumor proliferation. Additionally, it
induces E-selectin on tumor vessels and
consequent infiltration by cutaneous
lymphocyte-associated antigen-positive skin-
homing cluster of differentiation (CD8?)
cytotoxic T cells, and results in histological
evidence of tumor regression [67] and a
reduction in tumor cell numbers [68]. It
triggers a range of proinflammatory cytokines
including interferon alpha, tumor necrosis
factor alpha (TNF-a), and interleukin-12
(IL-12) [69].
It was first approved as a treatment for AKs in
2004 as a 3 times per week application, on the
bald scalp and face, for up to 16 weeks. This has
been more recently modified to a twice weekly
application, in 4-week application cycles, with a
4-week rest period between these cycles to
minimize treatment times and adverse events.
A 3.75% cream was first approved in 2010 for
once-nightly application for 2 weeks, followed
by a 2-week rest period without application,
which is then followed by another 2-week
treatment period [70].
Available preparations are 5% and 3.75%.
The 3.75% preparation allows for a shorter
duration of treatment over a larger skin
surface area (200 cm2 vs. 25 cm2 for 5% cream)
[71]. Absolute clearance rate is higher for the 5%
cream, at 45%, compared to 35% for daily use of
the 3.75% preparation [70], and the median
reduction in AK is 83% [72]. Use of the 5%
cream can give up to 57% clearance if used three
times per week for 16 weeks [73–75].
Cycle therapy is aimed at reducing local skin
reactions. In some studies, 5% Imiquimod was
applied 2–3 times weekly for 3–4 weeks, and
then reviewed after 4 weeks, with repeated
treatment if there were any residual lesions
[76, 77]. Complete clearance was achieved in up
to 82% of treatment areas. Imiquimod has also
been used in immunocompromised patients
with good results, and is generally regarded as
safe to use in this sub-group [78].
In 2010, Hanke et al. [79] performed two
placebo-controlled studies of daily application
of imiquimod 2.5% and 3.75% for the
treatment of AKs, for two 3-week cycles. This
looked at the balding scalp and face only. Up to
two packets of 250 mg each, were applied per
dose once daily, for two 3-week treatment
cycles, with a 3-week no-treatment interval.
Efficacy was assessed at 8 weeks post-treatment
and found that clearance rates for both
treatment options were superior to placebo
and had an acceptable safety profile. Complete
clearance in the 2.5% cream group was 25%,
and in the 3.75% cream group was 34%. Partial
clearance rates were higher.
A similar study by Swanson et al. [80] was
done to compare efficacy of 2.5% and 3.75%
cream in two 2-week cycles. Complete clearance
rate with daily application was 30.6% for 2.5%
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cream and 35.6% for 3.75%, which would
suggest that a shorter interval between
applications improves outcome. Side effects
include skin irritation and erythema, with
rarer consequences being flu-like symptoms
and lymphadenopathy [81].
In a randomized trial comparing imiquimod
against cryotherapy in the treatment of AK over
a 12-month period, it was found that repeated
cryotherapy (up to 4 sessions) achieved a higher
complete lesion clearance rate (85% vs. 66.9%),
while cosmetic outcome was better with
imiquimod (likely related to lower incidence
of hypopigmentation) [82]. In another split-face
study comparing imiquimod against PDT, the
authors found that there was no significant
difference in 100% or 75% response to either
treatment regimen, but mean lesion reduction
rate was superior in the PDT group [83].
Tolerability of 5% imiquimod was compared
to that of MAL–PDT in a randomized controlled
trial (n = 58) [84]. The patients were asked for
example, about pain, side effects and overall
satisfaction. Overall, the two treatments were
approximately equitable with the PDT group
scoring themselves as ‘very satisfied’ slightly
more frequently.
Recommended therapy for the face and
scalp, or large areas up to 200 cm2, could
therefore usefully be suggested as a short
course of 3.75% imiquimod cream daily for
2-week cycles, twice, to give 35.6% of patients
complete clearance. Licensed use of 5% cream is
for small skin areas up to 25 cm2, 2–3 times per
week for up to 4 months, although 1 month is
usually sufficient [85]. Evidence suggests 12- to
16-week treatment will give complete clearance
in 50% of patients [86]. If inflammation is
intolerable, frequency of application can be
reduced to once or twice per week with
preservation of efficacy. The addition of
lesion-directed cryosurgery prior to application
gives greater clearance than either therapy
alone [79].
There is evidence to suggest that patients
may develop T cell memory after treatment
with imiquimod, which is likely to reduce the
risk of developing further AKs. The 5%
preparation has also been shown to be
effective and safe in solid organ transplant
patients covering up to 100 cm2 skin surface
area [78, 87].
A sister drug called resiquimod, which is
currently an investigational product, is 10–100
times more potent than imiquimod.
A European phase II study of daily
applications 3 times per week for 4 weeks
found that clearance rates ranged from 40 to
74.2%. The lower concentrations were better
tolerated and as effective as the higher
concentrations [88].
Diclofenac Sodium 3% Gel: Anti-inflammatory
Agent
Diclofenac 3% gel is a nonsteroidal anti-
inflammatory formulated with 2.5%
hyaluronic acid. It is a popular treatment in
Germany, but not widely used in Australia.
Diclofenac is a cyclooxygenase (COX) inhibitor
exerting its antitumor effects via inhibition of
the COX-2 pathway and by inhibiting up
regulation of the arachidonic acid cascade. The
production of prostaglandins from arachidonic
acid may play a role in UV-B-induced skin
cancer [basal cell carcinoma (BCC) and SCC]
[89], and diclofenac’s inhibition of this cascade
may explain its efficacy in AK treatment. This
effect may be mediated via inhibition of
angiogenesis and induction of apoptosis. There
is evidence that diclofenac induces regression of
AKs [90, 91].
A 2005 meta-analysis of three randomized
trials (n = 364) found that treatment of AKs
with diclofenac gel led to complete resolution
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in approximately 40% of patients, whereas
there was only a 12% rate of complete
resolution of those treated with placebo [92].
Diclofenac resulted in 100% AK resolution in
50% of the subjects after 3 months of twice
daily application. This extended period of
treatment reduces compliance, but a shorter
duration is reportedly less efficacious [93].
Diclofenac treatment is well tolerated with
minimal irritation and inflammation. Adverse
reactions can include itch, xerosis, and contact
dermatitis [94].
Recommended dosing is twice per day for
90 days. When it is used after cryotherapy,
diclofenac has been shown to give greater
complete lesion clearance compared to
cryosurgery alone (64% vs. 32%, respectively)
[95]. Tolerance is better than the twice daily
application of 5-FU cream, but appears to be
slightly less effective when used alone. Long-
term data are restricted to a single uncontrolled
study [96] which shows similar efficacy at
12 months to ingenol mebutate (18%




Photodynamic therapy is a two-step procedural
field therapy, beginning with the topical
application of a photosensitizing agent to the
treatment area.
Photosensitizing agents are 5-ALA prescribed
in the form of an 8 mg adhesive patch, under
red light (630 nm); a 78 mg/g nanoemulsion
gel, under red light (630 nm) or a 20% solution
under blue light (417 nm) and MAL in the form
of a 16.8% cream, under red light (630 nm).
Licensing of these topical products varies
between countries, for example MAL is widely
available worldwide, but is the only preparation
available in Australia. The 5-ALA 20% solution
is only licensed in the US, Korea, Brazil, Mexico,
Argentina, Chile and Columbia. These prodrugs
are converted by the heme biosynthetic
pathway to protoporphyrin IX (PpIX).
After an incubation period whereby the
prodrug accumulates preferentially in
dysplastic actinic keratosis cells, the area is
then illuminated by an appropriate
wavelength light. This causes the activation of
PpIX and produces reactive oxygen species. The
ROSs produced upon light exposure cause
apoptosis and necrosis of target tissue,
resulting in cell death [97].
Treatment is currently aimed at patients who
have had difficulty adhering to topical field
therapies, AK lesions resistant to topical
therapies or those with concerns regarding the
cosmetic results of treatment [2]. A typical
regime for nonhyperkeratotic, non-pigmented
AKs would be the direct application of 20% ALA
topical solution to lesions on the face or the
scalp for 18–24 h, followed by blue light for
16 min and 40 s; or 16.8% MAL application for
3 h followed by red light for 7–10 min [98]. A
follow-up treatment is recommended for lesions
that have not completely resolved after 8 weeks.
A single treatment is used for thin or
moderately thick lesions, repeated after
3 months if not clinically cleared [99, 100].
PDT is usually well tolerated and clearance
rates of up to 90% after two applications have
been reported [101]. MAL is used most
commonly internationally as it selects and
penetrates dysplastic cells better than other
commercially available products [102]. PDT
with MAL achieved 100% resolution in up to
82% of subjects and cleared 90% of total AK
lesions in a 2008 randomized, double-blind,
placebo-controlled study by Pariser et al. [103].
In a recent study evaluating the effect that
ablative fractional laser resurfacing (AFXL) has
on improving PDT efficacy, it was found that
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AFXL-assisted PDT was significantly more
effective than PDT alone (complete lesion
clearance rate of 88% vs. 59% for grade 2–3
AK). The authors concluded that AFXL-assisted
PDT has a strong potential in treating AK,
especially thick lesions in field-cancerized skin
[104].
Wiegell et al. 2008 [105], and 2009 [106]
demonstrated that natural daylight
photodynamic therapy (DL-PDT) provides
similar AK clearance to conventional PDT
(c-PDT), is almost painless and is much
simpler to perform. DL-PDT involves the
application of MAL without occlusion, then
30 min later going outside into daylight for 2 h,
after which MAL is removed.
New formulations of ALA/MAL are being
trialed, and a recent multi-center study of
patients with mild-to-moderate AK to the
scalp/face found that PDT with BF-200 ALA
(Biofrontera, Leverkusen, Germany) (an ALA
nanoemulsion that improves ALA stability and
skin penetration) was superior to placebo for
complete clearance of 78.2%, and lesion
complete clearance rate of 90.4% at 3 months
post last PDT [107].
A self-adhesive, skin colored, thin 5-ALA
patch, applied directly to AK lesions without
crust removal was superior to cryotherapy in
clearing mild/moderate AK [108]. Side effects of
PDT include erythema, itching, edema,
exudation, and pain during exposure to light.
Local anesthetic nerve blocks or air-cooling for
pain relief may be required during PDT if the
discomfort is intolerable, with superior
analgesia found in those using nerve blocks
[109, 110]. The duration of healing rarely
exceeds 10 days. The significant advantage of
PDT is high satisfaction with respect to cosmetic
outcomes [98]. The optimal incubation times
for ALA/MAL and optimal light sources for PDT
are under ongoing investigation. Despite this, it
remains an effective lesion- and field-directed
therapy.
Ingenol Mebutate: Anti-neoplastic Agent
Ingenol mebutate is a new, Australian-
developed topical therapy, a diterpene ester
found in the sap of the Euphorbia peplus (petty
spurge) plant. It was approved for the treatment
of AK in the USA in 2012 and Australia in early
2013, but has not yet been included in the
current guidelines. Ingenol mebutate differs
from all other current topical treatments in
that it has a dual mechanism of action, which
may account for the efficacy after a much
shorter treatment period. It is currently
available in two preparations of 0.015% and
0.05%.
Firstly, there is rapid cellular necrosis
through the disruption of the plasma
membrane and mitochondrial swelling. This is
detectable within 1 h from onset of treatment
[111] and leads to cell death within 24 h in mice
[112].
Secondly, there is a specific neutrophil-
mediated, antibody-dependent cellular
cytotoxicity (ADCC), which targets any
remaining dysplastic epidermal cells [111].
Antibodies produced by B cells bind to
antigens on dysplastic epidermal cells, and
these then bind neutrophils which trigger
their cytotoxic mechanisms. ROS are released,
amongst other lytic agents, which causes the
destruction of the dysplastic epidermal cells.
Ingenol mebutate therefore induces both
chemo-ablative and immunostimulatory
effects after topical application. The rapid
destruction of AK lesions means treatment is
necessary for only 2 or 3 days: an unusually
short duration of treatment for a topical field
therapy. A phase IIa study by Siller et al. [113],
with 58 patients was conducted in Australia.
Five preselected lesions were treated with
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ingenol mebutate gel 0.0025, 0.01 or 0.05%, or
vehicle gel, on days 1 and 2 (Arm A), or days 1
and 8 (Arm B). The study showed that there
were no significant differences in tolerability or
efficacy in patients either treated 1 day or 7 days
apart. Treatment was well tolerated.
The most common local skin reactions were
erythema, scaling, and crusting. The highest
dose used (0.05%) achieved highest efficacy,
with clinical clearance of 71% of treated lesions.
Of all patients treated with 0.05% gel, 67% had
clinical clearance of at least four out of five
lesions [113].
In another study, a randomized, double-
blind, double-dummy, vehicle-controlled trial
was conducted across 22 centers in the USA,
where ingenol mebutate was assessed at three
dosing regimens for non-facial AK. The three
different treatment regimens in that trial were
significantly more effective than vehicle in
clearing AK. The partial clearance rates ranged
from 56% to 75.4% (vs. 21.7% for vehicle),
complete clearance rates ranged from 40% to
54.4% (vs. 11.7% for vehicle), and median
percentage decrease in baseline AK ranged
from 75% to 100% (vs. 0% for vehicle). All
arms of active treatment were well tolerated
[114].
Lebwohl et al. [115] found that complete
clearance of AK on the face and scalp treated
with ingenol mebutate 0.015% gel for 3 days
was 42.2% at the 8-week follow-up visit, and
34.1% for AKs on the trunk and extremities
using ingenol mebutate 0.05% gel for 2 days.
Local reactions of erythema, scaling,
vesiculation, depigmentation, swelling,
pruritus and crusting peaks at 4–8 days, and
may rarely last up to 30–55 days [115]. The
observational follow-up trial 12 months later
showed that a mean of 86% of the number of
lesions in the treatment area at baseline were
still clear. Approximately half the patients
developed a recurrence of one or more lesions
in the treated field.
A long-term follow-up study of ingenol
mebutate gel for the treatment of actinic
keratoses by Lebwohl et al. [116] was
completed in 2013. The results showed that
sustained clearance after 12 months was 46.1%
for patients treated on the face or scalp with
0.015% gel for 3 consecutive days, and 44.0%
for those treated on the trunk/extremities with
0.05% gel for 2 consecutive days. This is
considerably better than the 12-month
cryotherapy complete clearance rate of 4% as
described by Krawtchenko et al. [63]. The
estimated median times to new or recurrent
lesions in the treatment area are: 365 days for
the face or scalp and 274 days for the trunk or
extremities [116]. The recommended approved
therapy is therefore 0.015% gel to the face or
scalp for 3 consecutive days, and/or 0.05% gel
to the trunk or extremities for 2 consecutive
days. Follow-up can usually be recommended at
12 and 9 months, respectively, due to
recurrence rates.
Combining Therapeutic Modalities
Until more recently, there had been little
research into combined therapies for AK.
However, due to the increasing number of
treatment modalities, more effective
combinations are being studied [117–119].
An obvious choice would be to combine
lesion-directed cryotherapy and a field-directed
topical therapy. The use of 0.5% 5-FU cream
1 week prior to cryosurgery has been shown to
produce complete lesion clearance in a greater
proportion of patients than those treated with
cryosurgery alone (32.4% vs. 15%, respectively)
[120].
In a multi-center North American study,
cryosurgery followed by two cycles of 3.75%
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imiqumod applied daily for 2 weeks was
evaluated for the treatment of facial AK. This
was compared against a cryosurgery/placebo
group. The results showed that the median
total AK reductions were 86.5% and 50%, and
the complete clearance rates were 30.2% and
3.3% for the cryosurgery/imiquimod and
cryosurgery/placebo groups, respectively. Less
than 5% of subjects in each arm discontinued
the study due to adverse events. The authors
concluded that a short cyclical field treatment
of imiquimod following cryosurgery was well
tolerated and proven to be more effective than
cryosurgery alone [118]. In another study, more
patients treated with cryotherapy plus
imiquimod than cryotherapy plus vehicle
achieved complete clearance [121].
Another method is to combine topical
modalities. For example, 0.5% 5-FU with 10%
salicylic acid has been shown to provide more
patients with complete clearance than
diclofenac (55.4% vs. 32%, respectively) [122].
In a study conducted in Spain, PDT followed
by three times weekly of imiquimod for 4 weeks
(with a 1-month interval between the two
treatments) was found to provide better
clinical and histologic response than either
treatment as monotherapy for facial/scalp AK.
However, the difference in efficacy results
between the PDT and imiquimod against
imiquimod monotherapy arm are not
significant, while those between PDT and
imiquimod against PDT monotherapy were
significant. Combination PDT and imiquimod
was also found to elicit less intense local
reactions and better tolerance and satisfaction
than imiquimod monotherapy [117].
In a small pilot study conducted in the
Netherlands, pre-treatment of AK on dorsum
of hands with twice daily diclofenac 3% gel for
4 weeks followed by PDT 2 weeks later was
compared to a placebo gel/PDT group. There
were significant reductions in lesion numbers in
both groups. Between both groups, a significant
difference was only seen at 12 months after
PDT, whereby the diclofenac/PDT group has a
mean lesion score of 1.5 vs. 5.4 for the placebo/
PDT group. Pain during PDT was greater in the
diclofenac group. They concluded that both
treatments were effective in treating AK, with
the diclofenac group resulting in fewer AK at
12 months post-treatment [119].
Combining 70% glycolic acid with 5-FU has
shown a 92% reduction in the number of AKs
compared to a 20% reduction with chemical
peel alone [123]. In a recent study, a
combination of imiquimod and 5-FU once
daily for up to 12 weeks led to the complete
resolution of AK in ten out of ten patients [124],
and a similar study found that 5-FU in the
morning and imiquimod 5% at night for
1 week, repeated monthly for up to 3 months,
gave [90% complete clearance [125]. It was
noted that 17% of patients withdrew due to
adverse side effects in this study. More
combinations of topical therapy are under
investigation but are beyond the scope of this
discussion.
Oral retinoids are reserved for patients
suffering with multiple AKs and where several
SCCs are already developing, although evidence
for this is scant and use as a monotherapy is
most likely suboptimal [126]. It has been shown
that retinoids can help decrease the risk of
premalignant cells further developing into
tumors [127]. The use of topical retinoids in
the prevention of keratinocyte carcinoma has
been investigated without success so far [128].
Lastly, other products currently under
investigation as treatment for AKs include oral
nicotinamide [129], betulinic acid [130] and
piroxicam [131]. Further discussion is beyond
the scope of this article but may yield
interesting new adjuncts in the near future.
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CONCLUSION
Actinic keratosis is common amongst fair-
skinned patients exposed to significant
amounts of UV irradiation. Although the
chance of individual AK transforming to SCC is
not high, they are useful markers for sun damage
and skin cancer risk assessment. There is
increasing interest in combining therapies for
the treatment of AK, especially as the treatment
options are ever increasing. However, the
ultimate treatment choice will rest not only on
efficacy, but also associated adverse reactions,
cosmetic outcomes, accessibility, costs,
compliance, and patient choice. The
management of multiple AKs is a long-term
prospect, with no clear cure. The best approach
is the sequential treatment with a lesion-directed
and a field-directed therapy. Combination
therapies work well and should be adjusted
according to patient requirements [132].
It is an area that clearly warrants ongoing
research into methods of improving treatment
and prevention, in a bid to reduce the burden of
such a common disease on individuals and
health care services.
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